Telix Expands Board with Two Seasoned Directors Amid Global Growth Push
Event summary
- Telix appoints Maria Rivas, MD, and William Jellison as Non-Executive Directors effective May 11, 2026.
- Dr. Rivas brings 25+ years in late-stage clinical development and commercialization, including roles at Pfizer.
- Mr. Jellison has over 30 years of corporate finance experience, including CFO roles at Stryker Corporation.
- Appointments align with Telix's evolution as a dual-listed, global, commercial-stage biopharmaceutical company.
The big picture
Telix's board expansion reflects its transition to a global, commercial-stage biopharmaceutical company. The appointments of Dr. Rivas and Mr. Jellison bring critical expertise in clinical development, corporate finance, and U.S. public company governance, aligning with Telix's strategic goals. This move is part of a broader trend in the biopharma sector where companies are strengthening their boards to navigate complex regulatory environments and scale operations internationally.
What we're watching
- Governance Dynamics
- How the new directors' expertise in U.S. public company governance will influence Telix's strategic decisions.
- Execution Risk
- Whether Telix can effectively integrate the diverse experience of its expanded board into operational success.
- Global Expansion
- The pace at which Telix advances its commercial-stage biopharmaceutical portfolio with the new leadership insights.